Adipotide
Also known as: Prohibitin-TP01, CKGGRAKDC-GG-D(KLAKLAK)2
Prohibitin-Targeting Peptidomimetic | Experimental Anti-Obesity
Overview
Chimeric adipose-vasculature-targeted peptidomimetic targeting prohibitin/annexin A2 on white adipose tissue endothelium, delivering pro-apoptotic D-(KLAKLAK)2 motif. In obese primates it produced rapid fat loss with improved insulin resistance, yet development halted after Phase 1 due to kidney safety signals.
Key benefits
- Rapid fat-mass reduction via selective white adipose tissue vascular targeting
- Improved insulin sensitivity following adipose reduction
- Non-CNS peripheral mechanism distinct from appetite suppressants
Mechanism of action
CKGGRAKDC ligand homes to prohibitin/annexin A2 on white-fat endothelium; linked D-(KLAKLAK)2 disrupts mitochondrial membranes post-internalization, triggering localized endothelial apoptosis and adipocyte loss.
Molecular data
- Type
- Chimeric peptidomimetic
- Half-life
- Not established
Sequence
CKGGRAKDC-GG-D(KLAKLAK)2
Indications
What the research community uses this compound for, with self-reported effectiveness.
Weight Loss
Metabolic
Appetite Control
Dosing protocols
Common protocols by delivery method. Adjust the curve below to model accumulation in your own cycle.
Delivery method
| Protocol | Dose | Frequency | Duration |
|---|---|---|---|
| — | 0.43 mg/kg | Once daily | — |
| — | 0.10-0.75 mg/kg | Once daily (escalating tiers) | — |
Safety
Reported adverse effects, contraindications, and what to monitor on cycle.
Common side effects
- Mild creatinine elevation
- Electrolyte shifts
- Dose-dependent proximal tubule changes (reversible in primates)
Contraindications
- Pregnancy/lactation (not studied)
- Dehydration
- Concurrent nephrotoxic medications
Monitoring
- Serum creatinine weekly
- Blood urea nitrogen (BUN) weekly
- Urinalysis weekly
- Electrolytes weekly